The road less travelled: what options are available for patients with advanced squamous cell carcinoma?
|
|
- Asher Parrish
- 5 years ago
- Views:
Transcription
1 Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma?
2 Disclosures Honoraria for advisory board/consulting AstraZeneca Boehringer Ingelheim Clovis Eli Lilly Pfizer Roche Speaker s fee AstraZeneca Boehringer Ingelheim Eli Lilly Data safety monitoring board Merck Sharp & Dohme Genmab Regeneron Synta
3 Learning objective After this presentation, participants will be able to describe current and emerging treatment modalities (targeted, anti-angiogenesis, immunotherapy) for advanced squamous NSCLC summarize their efficacy and safety in recent clinical trials
4 Case discussion A 65-year-old male, former smoker Cough for 3 months, ECOG-1 Diagnosis: squamous cell carcinoma stage IV ECOG-1, Eastern Cooperative Oncology Group performance status score of 1. Courtesy of R. Pirker.
5 Case A (continued) Courtesy of R. Pirker.
6 Case A (continued) 65-year-old male, former smoker Cough for 3 months, ECOG-1 Diagnosis: squamous cell carcinoma stage IV Treatment? EGFR IHC score 200; PD-L1 5% EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; PD-L1, programmed death-ligand 1. Courtesy of R. Pirker.
7 Question 1 Which treatment would you start? 1. Cisplatin + gemcitabine 2. Cisplatin + gemcitabine + necitumumab 3. Platin + gemcitabine + bevacizumab 4. Pembrolizumab 5. Other
8 Metastatic NSCLC: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up 1 PD-L1 50% PS Pembrolizumab 2 PS 1 < 70 years Squamous NSCLC (stage IV) No driver mutation PS 2 < 70 years or PS 0 2 > 70 years PS cycles Platinum-based doublet a Necitumumab-cisplatingemcitabine if IHC EGFR +ve 4 6 cycles Carboplatin based doublet a Single agent (gemcitabine, vinorelbine, docetaxel) BSC a Cisplatin/gemcitabine; cisplatin/docetaxel; cisplatin/vinorelbine; carboplatin/paclitaxel; carboplatin/nab-paclitaxel. PS, performance status. 1. Based on Novello S, et al. Ann Oncol. 2016;27(Suppl 5):v Reck, M. et al. N Eng J Med. 2016;375:
9 OS (%) Cisplatin/gemcitabine ± necitumumab: SQUIRE Overall survival (n = 1,093) Number at risk Necitumumab + gemcitabine and cisplatin Necitumumab + gemcitabine and cisplatin Gemcitabine and cisplatin Censored patients Necitumumab* + gemcitabine and cisplatin (n = 545) HR: 0.84 (95% CI: ); p = 0.01 Median survival 11.5 months versus 9.9 months, 1-year survival rate 48% versus 43% Gemcitabine and cisplatin (n = 548) Patients censored, n (%) 127 (23) 106 (19) Median OS, months (95% CI) 11.5 ( ) 9.9 ( ) Stratified p value (log-rank) 0.01 Stratified HR (95% CI) 0.84 ( ) * 800 mg i.v. days 1 and Gemcitabine and cisplatin OS, overall survival. Reproduced from Thatcher N, et al. Lancet Oncol. 2015;16: , Elsevier Ltd. All rights reserved.
10 OS (%) Cisplatin/gemcitabine ± necitumumab: SQUIRE Overall survival (n = 935: subpopulation of patients with EGFR protein expression) Median OS, months Necitumumab + gemcitabine cisplatin 11.7 Gemcitabine cisplatin 10.0 HR (95% CI), p value 0.79 ( ), p = Necitumumab + gemcitabine cisplatin Gemcitabine cisplatin Time since randomization (months) HR: 0.79 (95% CI: ); p = Median survival 11.7 months versus 10.0 months Reproduced from Paz-Ares L, et al. Ann Oncol. 2016;27: , Oxford University Press.
11 Case discussion B 73-year-old female, never smoker Increasing dyspnoea at exertion during last two months; ECOG-1 CT scan CT, computerized tomography. Courtesy of R. Pirker.
12 Case B (continued) Courtesy of R. Pirker.
13 Case B (continued) 73-year-old female, never smoker Increasing dyspnoea at exertion during last two months; ECOG-1 CT scan: lesions in right & left lung, mediastinal lymph node, cervical lymph node Treatment? Bronchoscopy Diagnosis: squamous cell carcinoma of the lung stage IV, no driver mutation Courtesy of R. Pirker.
14 Question 2 Which treatment would you start? 1. Gemcitabine or vinorelbine 2. Carboplatin + gemcitabine, or carboplatin + vinorelbine 3. Carboplatin + paclitaxel 4. Pembrolizumab 5. Other
15 Lung cancer therapy in elderly patients: factors to be considered Patient-related factors age and life expectancy gender performance status co-morbidity, organ functions geriatric syndromes functional status convenience of administration side effects of drugs polypharmacy patient preference Tumour-related factors histological subtype molecular characteristics tumour stage tumour growth Costs, cost effectiveness value-based judgements Courtesy of R. Pirker.
16 First-line chemotherapy in elderly patients with advanced NSCLC phase 3 trials Vinorelbine > BSC (ELVIS) 1 Vinorelbine = gemcitabine = gemcitabine/vinorelbine (MILES) 2 Vinorelbine + gemcitabine > vinorelbine 3 Carboplatin + paclitaxel > vinorelbine or gemcitabine 4 Single agent ± cisplatin (MILES 3 and MILES 4) 5 BSC, best supportive care. 1. Gridelli C, et al. J Natl Cancer Inst.1999;91: Gridelli C, et al. J Natl Cancer Inst. 2003;95: Frasci G, et al. J Clin Oncol. 2000;13: Quoix E, et al. Lancet. 2011;378: Gridelli C, et al. J Clin Oncol. 2017;35 Suppl 15:abstract 9002.
17 Case B (continued) 73-year-old female, never smoker Increasing dyspnoea at exertion during last two months; ECOG-1 CT scan: lesions in right and left lung, mediastinal lymph node, cervical lymph node Chemotherapy (2 cycles of carboplatin + gemcitabine; 2 cycles of gemcitabine) resulted in symptom relief and radiological partial response haematotoxicity (leucopenia, anaemia) Bronchoscopy Diagnosis: squamous cell carcinoma of the lung stage IV Courtesy of R. Pirker.
18 Case B (continued) Before chemotherapy After chemotherapy Courtesy of R. Pirker.
19 Patients (%) Patients (%) Predicting chemotherapy toxicity in elderly patients Patients with lung (29%), GI (27%), gynaecologic (17%), breast (11%), GU (10%) or other (6%) cancers Toxicity grade 3 5 Predictive model based on age 72 hearing (fair or worse) haemoglobin < 11 (male) or < 10 g/dl (female) falls in last six months (one or more) creatinine clearance < 34 ml/min walking one block (limited, somewhat, or a lot) cytoxic drugs (dosing; number) taking medications (some help/unable) decreased social activity cancer type GI or GU Main toxicities leucopenia, anaemia fatigue, infection, dehydration Low Medium High Total risk score <70 MD-rated KPS (%) GI, gastrointestinal; GU, genitourinary; MD, physician; KPS, Karnofsky performance status. Hurria A, et al. J Clin Oncol. 2011;29:
20 Chemotherapy in elderly patients with advanced NSCLC Individualized therapy based on evidence, personal experience (judgement), and patient preference Performance status, co-morbidity, organ function, geriatric syndromes, social support, life expectancy, patient preference Chemotherapy protocols for first-line therapy fit patients: doublet or single agent vulnerable patients: consider single agent frail patients: no chemotherapy Expect increased toxicity Enhanced supportive care prophylaxis of emesis, obstipation, infection, and dehydration Aged over 80: no general recommendations Courtesy of R. Pirker.
21 Case discussion C 50-year-old male, heavy smoker Pain in left shoulder for several weeks; ECOG-1 CT scan: lesions in left upper lung, suspicious lesion in right adrenal gland CT-guided biopsy of the left lung Diagnosis: squamous cell carcinoma of the left lung, stage IV (?) PD-L1 negative Chemotherapy plus thoracic radiotherapy Courtesy of R. Pirker.
22 Case C (continued) Before chemotherapy After chemotherapy Courtesy of R. Pirker.
23 Question 3 Progression after chemotherapy (cisplatin + vinorelbine) and radiotherapy: which treatment would you start? 1. Docetaxel 2. Docetaxel + ramucirumab 3. Immune checkpoint inhibitor 4. Afatinib 5. Other
24 Metastatic NSCLC: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up Progression after front-line treatment (SCC stage IV) PS 0 2 PS 3 4 Nivolumab Pembrolizumab if PD-L1 > 1% Docetaxel Docetaxel + ramucirumab Erlotinib Afatinib BSC SCC, squamous cell carcinoma. Based on Novello S, et al. Ann Oncol. 2016;27(Suppl 5):v1-27.
25 Recent advances in pre-treated patients with advanced squamous NSCLC Docetaxel + ramucirumab (REVEL) 1 Afatinib in squamous cell NSCLC (LUX-Lung 8) 2 Nivolumab 3 Pembrolizumab 4 Atezolizumab 5 1. Garon EB, et al. Lancet. 2014;384: Soria JC, et al. Lancet Oncol. 2015;16: Brahmer J, et al. N Eng J Med. 2015;373: Herbst RS, et al. Lancet. 2016;387: Rittmeyer A, et al. Lancet. 2017;389:
26 OS (%) Docetaxel ± ramucirumab (10 mg/kg): REVEL Ramucirumab + docetaxel Placebo + docetaxel Censored Time (months) Number at risk Ramucirumab + docetaxel Placebo + docetaxel OS: HR 0.86 (95% CI: ), p = Median (95% CI) Censoring rate (%) Ramucirumab + docetaxel 10.5 months ( ) 31.8 Placebo + docetaxel 9.1 months ( ) 27.0 Ramucirumab vs placebo, Stratified HR (95% CI), p value 0.86 ( ), p = Reproduced from Garon EB, et al. Lancet 2014;384: , Elsevier Ltd. All rights reserved.
27 OS (%) Afatinib versus erlotinib in squamous cell carcinoma of the lung: LUX-Lung Afatinib Erlotinib Afatinib Time (months) Number at risk Afatinib Erlotinib OS: HR 0.81 (95% CI: ), p = Erlotinib Median OS, months (95% CI) 7.9 ( ) 6.8 ( ) Soria JC, et al. Lancet Oncol. 2015;16:
28 OS (% of patients) OS (% of patients) Nivolumab versus docetaxel in advanced NSCLC: overall survival Nivolumab Docetaxel Nivolumab Docetaxel Time (months) Number at risk Nivolumab Docetaxel Squamous 1 HR 0.59 (95% CI: ) p < Time (months) Number at risk Nivolumab Docetaxel Adenocarcinoma 2 HR 0.73 (95% CI: ) p = Brahmer J, et al. N Eng J Med. 2015;373: Borghaei H, et al. N Eng J Med. 2015;373:
29 OS (%) OS (%) Pembrolizumab (2 or 10 mg/kg) versus docetaxel in advanced NSCLC: overall survival Number at risk Pembrolizumab 2 mg/kg Pembrolizumab 10 mg/kg Docetaxel Pembrolizumab 2 mg/kg Pembrolizumab 10 mg/kg Docetaxel Pembrolizumab 2 mg/kg Pembrolizumab 10 mg/kg Docetaxel Time (months) Number at risk Pembrolizumab 2 mg/kg Pembrolizumab 10 mg/kg Docetaxel PD-L1 50% Pembrolizumab 10 mg/kg every 3 weeks: HR 0.50 (95% CI: ); p < Pembrolizumab 2 mg/kg every 3 weeks: HR 0.54 (95% CI: ); p = All patients Pembrolizumab 10 mg/kg every 3 weeks: HR 0.61 (95% CI: ); p < Pembrolizumab 2 mg/kg every 3 weeks: HR 0.71 (95% CI: ); p = Reproduced from Herbst RS, et al. Lancet. 2016;387: , Elsevier Ltd. All rights reserved.
30 Conclusions Necitumumab added to first-line chemotherapy with cisplatin plus gemcitabine improves survival of patients with advanced squamous cell carcinoma of the lung Elderly patients benefit from first-line chemotherapy with single agents or well-tolerated doublets, but require enhanced supportive care measures Ramucirumab added to docetaxel improves survival of patients with advanced NSCLC who have previously been treated with chemotherapy
31 Relative risk Relative risk Benefits of stopping smoking: UK Million Women Study Death from any cause 4 Death from lung cancer Current smokers Women who never smoked Current smokers Women who never smoked Age of former smokers at cessation (year) Age of former smokers at cessation (year) Jha P, Peto R. N Eng J Med. 2014;370:60-8.
32 Disclaimer enduring materials The views expressed in the following presentations are those of the individual presenting speakers The presentations may discuss therapeutic products that have not been approved, or off-label use of certain products These presentations are for educational purposes only and should not be reproduced or distributed in any way If you wish to reproduce, store in a retrieval system, transmit in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner Excerpta Medica emphasizes that the content of these materials/this educational activity is provided for general educational purposes only, and should not in any way be considered as advisory. It is the responsibility of the health care professional to verify all information and data before treating patients or using any therapies described
Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationConsiderations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit?
Considerations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit? Barbara Melosky University of British Columbia, British Columbia Cancer Agency Faculty Disclosure
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationRecent Therapeutic Advances in Squamous Cell Carcinoma of the Lung
Recent Therapeutic Advances in Squamous Cell Carcinoma of the Lung 2017 Conversations in Oncology in Shanghai, China Prof. Shun Lu Shanghai Lung Cancer Center Shanghai Chest Hospital Affiliated to Medical
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationA Case Review: Treatment-Naïve Patient with Advanced NSCLC: Smoker with Metastatic Squamous Cell Tumor
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationOverall survival in non-small cell lung cancer what is clinically meaningful?
Editorial Overall survival in non-small cell lung cancer what is clinically meaningful? Klaus Fenchel 1, Ludger Sellmann 2, Wolfram C. M. Dempke 3 1 Medical School Hamburg (MSH), Hamburg, Germany; 2 University
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationSecond-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
More informationUNDERSTANDING SQUAMOUS CELL LUNG CANCER
UNDERSTANDING SQUAMOUS CELL LUNG CANCER A guide for patients and caregivers FREE TO BREATHE SUPPORT LINE (844) 835-4325 A FREE resource for lung cancer patients & caregivers About this brochure This brochure
More informationPROGRESSION AFTER THIRD GENERATION TKI
PROGRESSION AFTER THIRD GENERATION TKI What next? National Cancer Center Hospital Yuichiro Ohe, MD Name of lead presenter Yuichiro Ohe employee of company and/or profit-making organization adviser of company
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationCME Information. ResearchToPractice.com/ThoracicCancers17/Nontargeted 1
CONSENSUS OR CONTROVERSY: Clinical Investigators Provide Perspectives on the Treatment of Metastatic Non-Small Cell Lung Cancer in Patients without Targetable Tumor Mutations CME Information TARGET AUDIENCE
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationNCCN Non Small Cell Lung Cancer V Meeting July 8, 2016
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationSystemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and the Lung Cancer Disease Site Group
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationAlgoritmo de tratamiento del CNMP escamoso. Jesús Corral, MD Thoracic Oncology Unit HUVR-Oncoavanze, Sevilla
Algoritmo de tratamiento del CNMP escamoso Jesús Corral, MD Thoracic Oncology Unit HUVR-Oncoavanze, Sevilla Agenda CNMP escamoso vs no escamoso: diferencias? Opciones de tratamiento 1L Opciones de tratamiento
More informationTumor Board Discussions: Case 1
Tumor Board Discussions: Case 1 David S. Ettinger, MD The Alex Grass Professor of Oncology Johns Hopkins University School of Medicine Baltimore, Maryland Case #1 50-year-old Asian female, never smoker
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationSystemic therapy in early stage NSCLC. Disclosures
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationAccepted Manuscript. C. Gridelli, B. Besse, J.R. Brahmer, L. Crino, E. Felip, F. de Marinis. S (16) /j.cllc
Accepted Manuscript The evolving role of nivolumab in non-small-cell lung cancer for second-line treatment: a new cornerstone for our treatment algorithms. Results from an International Experts Panel Meeting
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationSecond-line afatinib for advanced squamous cell carcinoma of the lung: analysis of afatinib long-term responders in the Phase III LUX-Lung 8 trial
Second-line afatinib for advanced squamous cell carcinoma of the lung: analysis of afatinib long-term responders in the Phase III LUX-Lung 8 trial lenwood oss, Manuel Cobo, Shun Lu, Konstantinos Syrigos,
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationEGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy?
Review Article EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy? Robert Pirker Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria Corresponding
More informationTechnology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531
Pembrolizumab for untreated PD- L1-positive metastatic non-small-cell lung cancer Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531 NICE 2018. All rights reserved. Subject
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationSingle Technology Appraisal (STA)
Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response
More informationMaintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
More informationLung Cancer in Paul Wheatley-Price BSc, MBChB, MRCP (UK), MD
Lung Cancer in 2015 Paul Wheatley-Price BSc, MBChB, MRCP (UK), MD Assistant Professor, Division of Medical Oncology, Department of Medicine, University of Ottawa 1 Disclosures Honorarium for advisory boards,
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationCarcinoma escamoso: optimizacio n de tratamiento. Noemi Reguart Hospital Clínic Barcelona
Carcinoma escamoso: optimizacio n de tratamiento Noemi Reguart Hospital Clínic Barcelona National Cancer Database (US) 80% 70% 60% 50% 40% 30% Incidence of SCC 27% 20% 10% 0% 1998-1999 2000-2003 2004-2007
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationBiomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano
Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano Unit of Pathology Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia,Italy p.graziano@operapadrepio.it Disclosure
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationCetuximab in non-small-cell lung cancer
Review Article Cetuximab in non-small-cell lung cancer Robert Pirker, Martin Filipits Department of Medicine I, Medical University Vienna, 1090 Vienna, Austria Corresponding to: Robert Pirker, MD. Department
More informationIMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER A guide for patients and caregivers TM Content is consistent with the Oncology Nursing Society Standards and Guidelines. The ONS Seal of Approval does not
More informationTechnology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227 NICE 2018. All rights reserved. Subject to
More informationin combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationCollaborative Practice in the Management of Patients With Cancer. Non-Small Cell Lung Cancer: Management of Patients on Cytotoxic Chemotherapy
Collaborative Practice in the Management of Patients With Cancer Non-Small Cell Lung Cancer: Management of Patients on Cytotoxic Chemotherapy Program Chair Beth Eaby-Sandy, MSN, CRNP, OCN Abramson Cancer
More informationTake home message. Emilio Bria. II SESSIONE: Immunoterapia nel tumore del polmone
II SESSIONE: Immunoterapia nel tumore del polmone Take home message Emilio Bria Oncologia, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Roma, 28 Marzo 2017
More informationImmunotherapeutic Approaches in the Treatment of NSCLC. Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary
01 Immunotherapeutic Approaches in the Treatment of NSCLC Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary Outline 02 Review the concept and evolution of immunotherapy in the treatment of cancer Discuss
More informationJ. C.-H. Yang 1, L.V. Sequist 2, S. L. Geater 3, C.-M. Tsai 4, T. Mok 5, M. H. Schuler 6, N. Yamamoto 7, D. Massey 8, V. Zazulina 8, Yi-Long Wu 9
Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: Findings from three prospective trials of afatinib in EGFR mutation-positive lung cancer J. C.-H. Yang 1, L.V. Sequist
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationTargeted Therapies in the Management of Non-Small Cell Lung Cancer. A Multi-Disciplinary Approach
Targeted Therapies in the Management of Non-Small Cell Lung Cancer A Multi-Disciplinary Approach Course Faculty Medical Oncologists: Dr. Barb Melosky British Columbia Cancer Agency, Vancouver, BC Dr. Jeff
More informationHow I Treat Stage IV Non Small Cell Lung Cancer in the Absence of Any Actionable Oncogenic Driver
CLINICAL PERSPECTIVE How I Treat How I Treat Stage IV Non Small Cell Lung Cancer in the Absence of Any Actionable Oncogenic Driver Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationPRACTICE GUIDELINE SERIES
ELLIS et al. PRACTICE GUIDELINE SERIES The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent nonsmall-cell lung cancer: a Canadian
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More information